Latest Articles
ERS regulates endometrial epithelial cell autophagy through XBP1s -mediated activation of the PI3K/AKT pathway - Nature.com
ERS regulates endometrial epithelial cell autophagy through XBP1s -mediated activation of the PI3K/AKT pathway Nature.com
Published: Feb. 18, 2025, 5:33 p.m.
ACR-368 OncoSignature Assay Receives FDA Breakthrough Device Designation for Endometrial Cancer - Pharmacy Times
ACR-368 OncoSignature Assay Receives FDA Breakthrough Device Designation for Endometrial Cancer Pharmacy Times
Published: Feb. 10, 2025, 2:34 p.m.
FDA Grants Breakthrough Status to Endometrial Cancer Assay - www.oncnursingnews.com/
FDA Grants Breakthrough Status to Endometrial Cancer Assay www.oncnursingnews.com/
Published: Feb. 9, 2025, 3:01 p.m.
FDA grants breakthrough designation for Acrivon’s endometrial cancer assay - Medical Device Network
FDA grants breakthrough designation for Acrivon’s endometrial cancer assay Medical Device Network
Published: Feb. 6, 2025, 10 a.m.
FDA grants breakthrough designation for Acrivon’s endometrial cancer assay - Yahoo! Voices
FDA grants breakthrough designation for Acrivon’s endometrial cancer assay Yahoo! Voices
Published: Feb. 6, 2025, 9:54 a.m.
FDA Grants Breakthrough Device Designation to ACR-368 OncoSignature Assay for Endometrial Cancer - OncLive
FDA Grants Breakthrough Device Designation to ACR-368 OncoSignature Assay for Endometrial Cancer OncLive
Published: Feb. 5, 2025, 5:17 p.m.
Acrivon Therapeutics Announces FDA has Granted Breakthrough - GlobeNewswire
Acrivon Therapeutics Announces FDA has Granted Breakthrough GlobeNewswire
Published: Feb. 5, 2025, 1:19 p.m.
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer - The Manila Times
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer The Manila Times
Published: Feb. 5, 2025, 1:07 p.m.
Acrivon's AI-Powered Cancer Test Achieves 62.5% Response Rate, Earns FDA Breakthrough Status - StockTitan
Acrivon's AI-Powered Cancer Test Achieves 62.5% Response Rate, Earns FDA Breakthrough Status StockTitan
Published: Feb. 5, 2025, 1 p.m.
Breakthrough blood test for endometriosis developed - Lab + Life Scientist
Breakthrough blood test for endometriosis developed Lab + Life Scientist
Published: Jan. 10, 2025, 4 a.m.
Link copied to clipboard!